Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial

The Lancet

Volumn 377, Issue 9782, 2011, Pages 2013-2022

  Bousser, Marie Germaine ^a   Amarenco, Pierre ^a   Chamorro, Angel ^b   Fisher, Marc ^c   Ford, Ian ^d   Fox, Kim M ^e   Hennerici, Michael G ^f   Mattle, Heinrich P ^g   Rothwell, Peter M ^h   De Cordoüe, Agnès ⁱ   Fratacci, Marie Dominique ⁱ  

^a INSERM   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF BERN   (Switzerland)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; TERUTROBAN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK;

EID: 79958770159     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60600-4     Document Type: Article

References (25)

1. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577-617. (Pubitemid 43732031)
2. Bousser MG. Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc Dis 2009; 27 (suppl 3): 12-19.
3. Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 2010; 9: 273-84.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
5. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
6. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13. (Pubitemid 26402780)
7. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51.
8. Diener HC, Bogousslavsky J, Brass LM, et al, on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-37.
9. Shinohara Y, Katayama Y, Uchiyama S, et al, for the CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-68.
10. Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121: 171-79.
11. Chamorro A. TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 2009; 27 (suppl 3): 20-7.
12. Viles Gonzalez JF, Fuster V, Corti R, et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J 2005; 26: 1557-61. (Pubitemid 41373499)
13. Bousser MG, Amarenco P, Chamorro A, et al. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study. Cerebrovasc Dis 2009; 27: 509-18.
14. Bousser MG, Amarenco P, Chamorro A, et al. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Cerebrovasc Dis 2009; 27: 608-13.
15. Fiessinger JN, Bounameaux H, Cairols MA, et al. Thromboxane antagonism with terutroban in peripheral arterial disease: the TAIPAD study. J Thromb Haemost 2010; 8: 2369-76.
16. Bal dit Sollier C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, Drouet L. Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis 2009; 28: 505-13.
17. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol 2009; 53: 667-77.
18. Belhassen L, Pelle G, Dubois Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41: 1198-204. (Pubitemid 36384909)
19. Shi Y, Man RY, Vanhoutte PM. Two isoforms of cyclooxygenase contribute to augmented endothelium-dependent contractions in femoral arteries of 1-year-old rats. Acta Pharmacol Sin 2008; 29: 185-92. (Pubitemid 351178432)
20. Cheng Y, Austin SC, Rossa B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539-541. (Pubitemid 34408674)
21. Serruys PW, Rutsch W, Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation 1991; 84: 1568-80.
22. Savage MP, Goldberg S, Bove AA, et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 1995; 92: 3194-200.
23. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994; 89: 588-95.
24. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-28. (Pubitemid 30470586)
25. Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111: 334-42. (Pubitemid 40165341)